Discontinuation of growth hormone (GH) treatment during the transition phase is an important factor determining the phenotype of young adults with nonidiopathic childhood-onset GH deficiency.
Kołtowska-Häggström
Maria
M
KIGS/KIMS Medical Outcomes, Pfizer Health AB, Endocrine Care, SE-190 91 Sollentuna, Sweden. maria.koltowska-haggstrom@pfizer.com
Geffner
Mitchell E
ME
Jönsson
Peter
P
Monson
John P
JP
Abs
Roger
R
Hána
Václav
V
Höybye
Charlotte
C
Wollmann
Hartmut A
HA